Top Markets
#1 GEKKO GEKKO +51.79%
#2 Helium Helium +44.71%
#3 ADO Protocol ADO Protocol +38.80%
#4 Prom Prom +34.38%
#5 Pons Pons +32.43%
#6 StonkBroker StonkBroker +31.49%
#7 TENDIES TENDIES +27.68%
#8 Collector Crypt Collector Crypt +27.15%
#9 龙虾 (Lobster) 龙虾 (Lobster) +21.71%
#10 Cysic Cysic +20.11%
Coin of the day
GEKKO GEKKO
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
Jiangsu Yahong Meditech Co Ltd Jiangsu Yahong Meditech Co Ltd

Jiangsu Yahong Meditech Co Ltd

688176
Classifica tra le azioni #9583
Established in 2010 and headquartered in Shanghai, China, Jiangsu Yahong... Established in 2010 and headquartered in Shanghai, China, Jiangsu Yahong Meditech Co., Ltd. is a biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapeutic drugs. Its primary focus lies in medicines targeting genitourinary system cancers, though its pipeline extends to a variety of other diseases, serving both domestic Chinese and international markets. The company's clinical-stage pipeline features several key candidates. Notably, two compounds, APL-1202 (an anti-tumor drug) and APL-1706 (an agent drug), are both undergoing Phase III trials for the treatment of non-muscle invasive bladder cancer. Another promising candidate, APL-1501, an oral MetAP inhibitor, is currently in Phase I testing for addressing urinary system tumors and drug-resistant urinary tract infections. Furthermore, APL-1702, a photodynamic therapy product, is in Phase III for tackling cervical high-grade squamous intraepithelial lesions that arise from HPV infections. Beyond these clinical programs, Jiangsu Yahong Meditech is actively exploring targeted protein degraders in its preclinical phase. This includes ASN-1764, aimed at triple-negative breast cancer; ASN-1780, intended for metastatic castration-resistant prostate cancer; and APL-1901, designed to treat ER-positive breast cancer. The company's developmental efforts also encompass APL-1401, targeting moderately to severely active ulcerative colitis, and ASN-1733, for combating Acinetobacter baumannii infection.
Prezzo delle azioni
$1.72
Ultima sincronizzazione: 2026-08-28
Capitalizzazione di mercato
$985.07M
Variazione (1 giorno)
-0.50%
Variazione (1 anno)
6.01%
Paese
CN
Scambia Jiangsu Yahong Meditech Co Ltd (688176)

Categoria

Healthcare
Margine operativo per Jiangsu Yahong Meditech Co Ltd (688176)
Margine operativo al 2026 TTM: 0.00%
Secondo gli ultimi rapporti finanziari e il prezzo delle azioni di Jiangsu Yahong Meditech Co Ltd, il margine operativo attuale (TTM) è 0.00%. Alla fine del 2026, il margine operativo era 0.00%.
Storico del margine operativo per Jiangsu Yahong Meditech Co Ltd da 2026 a 2026
Margine operativo alla fine di ogni anno
Anno Margine Operativo Cambia
Non abbastanza dati per le date fornite.
Margine operativo per aziende simili o concorrenti
Azienda Margine Operativo Differenza del margine operativo Il paese
MERCK Kommanditgesellschaft auf Aktien MERCK Kommanditgesellschaft auf Aktien
MERCK Kommanditgesellschaft auf Aktien
MER.SW
0.00% -
DE
Merck KGaA Merck KGaA
Merck KGaA
MRK.DE
0.00% -
DE
Takeda Pharmaceutical Company Limited Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited
4502.T
0.00% -
JP
Galderma Group AG Galderma Group AG
Galderma Group AG
GALD.SW
0.00% -
CH
Sun Pharmaceutical Industries Limited Sun Pharmaceutical Industries Limited
Sun Pharmaceutical Industries Limited
SUNPHARMA.NS
22.93% -
IN
Cos'è l'Margine operativo di un'azienda?
L'Margine operativo è un indicatore chiave per valutare la redditività di un'azienda. Margini operativi più elevati sono generalmente preferibili poiché indicano che l'azienda riesce a vendere i propri prodotti o servizi a un prezzo significativamente superiore rispetto ai costi di produzione. Si calcola dividendo gli utili per i ricavi.